Final Thoughts The Tirzepatide + Niacinamide Injection represents a promising and customised option for those seeking advanced metabolic and weight-management support
Our skilled team will work closely with you to create a tailored treatment plan that aligns with your unique needs and goals
NICE guidance on obesity management (CG189 and recent technology appraisals) recommends a stepwise approach: First-line: Lifestyle interventions including dietary modification, increased physical activity, and behavioural support Pharmacotherapy: Consider when BMI 35 kg/m (or 30 kg/m with comorbidities) and lifestyle measures have been insufficient Licensed options: Orlistat remains a primary pharmacological option in NHS formularies, with GLP-1 receptor agonists like semaglutide (Wegovy) now available through specialist services for those with BMI 35 kg/m (or 30 kg/m with comorbidities) and at least one weight-related comorbidity Bariatric surgery: Considered for those with BMI 40 kg/m (or 35 kg/m with comorbidities) when other measures have failed NICE guidance emphasises using licensed medications with established safety profiles and does not recommend combining weight loss drugs without robust evidence
Discuss any dosing modifications with your prescriber before implementation
To provide timely, complementary evidence, we conducted a comparison of tirzepatide and semaglutide in patients at low, moderate and high cardiovascular risk who were diagnosed with obesity and type 2 diabetes and subgroups with specific cardiovascular conditions
Use this only to understand, not to change, your prescribed dose
)
.png)
